Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors
Eli M Soyfer, Benjamin J Lee, Abraham J Qavi, Selma Masri, Angela G Fleischman, Farshid Dayyani · 2026
Read Real-world evidence for the impact of circadian clock on the benefit from immune checkpoint inhibitors in solid tumors by Eli M Soyfer, Benjamin J Lee, Abraham J Qavi, Selma Masri, Angela G Fleischman, Farshid Dayyani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13523368.txt.
Description
Eli M Soyfer and colleagues test whether the time of day of immunotherapy infusions affects cancer outcomes in a 2026 real-world study. Nearly one thousand patients receiving checkpoint inhibitor drugs for solid tumors at one health system between 2018 and 2022 were grouped by whether infusions started before or after noon. Disease control, meaning shrinkage or stability, was the main outcome.
Early infusion was linked to higher disease control, at just under half of patients versus two fifths for later infusion. The association survived adjustment for stage, age, and ethnicity, and held across sex, age, stage, and drug subgroups, as well as in matched and sensitivity analyses. Evidence in the Hispanic subgroup was inconclusive because of small numbers. The authors call for prospective trials of treatment timing.
Catalog record
| CREATOR | Eli M Soyfer, Benjamin J Lee, Abraham J Qavi, Selma Masri, Angela G Fleischman, Farshid Dayyani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28508 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |